A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 73-77

  Mariano, Caroline ^a   Bosdet, Ian ^a   Karsan, Aly ^a   Ionescu, Diana ^a   Murray, Nevin ^a   Laskin, Janessa J ^a   Zhai, Yongliang ^b   Melosky, Barbara ^a   Sun, Sophie ^a   Ho, Cheryl ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; EGFR; Gefitinib; Population based; Second line; TKI

Indexed keywords

GEFITINIB; NAVELBINE; PEMETREXED; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY;

CHEMOTHERAPY; EGFR; GEFITINIB; POPULATION-BASED; SECOND-LINE; TKI;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PACLITAXEL; PLATINUM COMPOUNDS; POPULATION GROUPS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891736958     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.007     Document Type: Article

References (29)

1. Aisner D.L., Marshall C.B. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012, 138(September (3)):332-346.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(September (10)):947-957.
3. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30(April (10)):1122-1128.
4. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(March (3)):239-246.
5. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(February (2)):121-128.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(June (25)):2380-2388.
7. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(August (8)):735-742.
8. Chih-Hsin Yang J., Schuler M., Yamamoto N., O'Byrne K.J., Hirsh V., Mok T., et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012, 30(Suppl.).
9. Ku G.Y., Haaland B.A., de Lima Lopes G. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011, 74(December (3)):469-473.
10. Nishino M., Jackman D.M., Hatabu H., Yeap B.Y., Cioffredi L.A., Yap J.T., et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010, 195(September (3)):W221-W228.
11. Mok T., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. Phase III, randomized, open label first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced small cell lung cancer (IPASS). Ann Oncol 2008, 19(Suppl 8.).
12. Zhou C., Long Wu Y., Liu X., Wang C., Chen G., Feng Feng J., et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Abstract 7520. J Clin Oncol 2012, 30.
13. Inoue A., Kobayashi K., Maemondo M., Sugawara S., Oizumi S., Isobe H., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013, 24(January (1)):54-59.
14. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). Abstract 7521. J Clin Oncol 2012, 30.
15. Maemondo M., Minegishi Y., Inoue A., Kobayashi K., Harada M., Okinaga S., et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 2012, 7(September (9)):1417-1422.
16. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(December (36)):6251-6266.
17. Azzoli C.G., Temin S., Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract 2012, 8(January (1)):63-66.
18. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29(May (15)):2121-2127.
19. Giaccone G., Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011, 37(October (6)):456-464.
20. Ou S.H. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrapα A review of the clinical evidence. Crit Rev Oncol Hematol 2012, 83(September (3)):407-421.
21. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(May (5)):528-538.
22. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29(August (24)):3307-3315.
23. Stabile L.P., Rothstein M.E., Keohavong P., Lenzner D., Land S.R., Gaither-Davis A.L., et al. Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2010, 2(December (4)):2153-2170.
24. 2013. Available at: (accessed 28.02.13). http://www.clinicaltrials.gov/.
25. Bai H., Wang Z., Chen K., Zhao J., Lee J.J., Wang S., et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012, 30(September (25)):3077-3083.
26. Nishie K., Kawaguchi T., Tamiya A., Mimori T., Takeuchi N., Matsuda Y., et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012, 7(November (11)):1722-1727.
27. Nishino M., Cardarella S., Dahlberg S.E., Jackman D.M., Ramaiya N.H., Hatabu H., et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 79(March (3)):283-288.
28. Kim Y.H., Fukuhara A., Mishima M. Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive diseaseα. Case Rep Oncol 2011, 4(September (3)):470-474.
29. Ellis P., Verma S., Sehdev S., Younas J., Leighl N. Implementation of a national EGFR testing strategy in a publicly funded health system. J Thorac Oncol 2011, 6(Suppl. 2):S1513.